In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...

Many novel treatment approaches are being investigated to halt progression of geographic atrophy (GA) or, potentially, even reverse the retinal damage. The major categories include novel complement ...

CTx001 is an investigational AAV-based gene therapy designed to modulate multiple pathways of the complement system Opti-GAIN is a first-in-human trial to evaluate the safety, tolerability, and ...

FDA approval enables Complement Therapeutics to start the Opti-GAIN phase 1/2 trial for CTx001 in GA secondary to AMD. CTx001 is an AAV-based gene therapy delivering a truncated Complement Receptor 1 ...

DENVER--(BUSINESS WIRE)--Cascade Bio, an industrial biotech company enabling enzyme-based processes, has secured $6M to accelerate the shift from petrochemicals to biomanufacturing. The funding ...

Forbes contributors publish independent expert analyses and insights. Scott Hutcheson teaches leadership at Purdue University. In biology, nothing changes all at once. A single cell fires, a chemical ...

Acute chest syndrome (ACS), a form of lung injury associated with sickle cell disease (SCD), is driven by the abnormal activation of a part of the immune system known as the complement cascade, a ...

Sanofi SNY has announced that the FDA has granted a fast-track designation to its one-time intravitreal gene therapy, SAR446597, for the treatment of geographic atrophy (GA) due to age-related macular ...

Designation earned for a one-time intravitreal gene therapy designed to inhibit two key complement cascade pathways Geographic atrophy is an advanced form of dry age-related macular degeneration, that ...